Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ritonavir

« Back to Dashboard

Summary for Generic Name: ritonavir

Tradenames:1
Patents:17
Applicants:2
NDAs:4
Drug Master File Entries: see list21
Suppliers: see list1
Therapeutic Class:Antivirals

Clinical Trials for: ritonavir

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Status: Completed Condition: HIV Infections; Hyperlipidemia

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Status: Completed Condition: Acquired Immunodeficiency Syndrome

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
Status: Completed Condition: Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
Status: Active, not recruiting Condition: HIV Infections

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants
Status: Completed Condition: Healthy

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects
Status: Completed Condition: HIV Infections

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Status: Active, not recruiting Condition: HIV Infections

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.
Status: Completed Condition: HIV; Cardiovascular Disease

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
Status: Active, not recruiting Condition: Hyperlipidemia; HIV

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes5,948,436*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes6,703,403*PED<disabled>Y<disabled>
Abbott
NORVIR
ritonavir
CAPSULE;ORAL020680Mar 1, 1996DISCNNo5,948,436*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659Mar 1, 1996RXYes5,674,882*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417Feb 10, 2010RXYes8,268,349*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc